Medivir participates in the partner and investor conferences Nordic Health Summit in Japan/Korea and BIO KOREA 2026

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need, announces that the company will participate in two partner and investor conferences in Asia in the coming weeks.

The Nordic Health Summit (NHS) Japan & South Korea is organized by Business Sweden in Tokyo and Seoul on April 23–30 and aims to connect Nordic life science companies with Japanese and Korean companies and investors. In addition to meeting potential partners at the matchmaking session and discussing potential collaborations for the company's two lead drug candidates fostrox and MIV-711, Medivir has also been selected to present to all participants at the meeting in Tokyo.

Medivir's CEO Jens Lindberg will also attend BIO KOREA in Seoul on April 28–30. As one of Asia's premier life science gatherings, the conference attracted more than 700 companies and around 30,000 visitors from 60 countries in 2025.

Jens Lindberg, CEO of Medivir, comments: "Conferences like NHS and BIO KOREA are important platforms for engaging with potential partners. We look forward to presenting our two lead programs — fostrox in advanced liver cancer and MIV-711 in Osteogenesis Imperfecta — both of which address significant unmet medical needs with clear blockbuster potential. I look forward to many productive conversations about potential collaborations."